TICKERNERD
Menu
IARTIARTHealthcare · Medical Devices

IART Stock Forecast: Integra LifeSciences Holdings Corp. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$15
+8.80% on the day

The 12 Wall Street analysts covering Integra LifeSciences Holdings Corp. hold a median 12-month price target of $14 — -5.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 4 Nov 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$1.1B
Ticker Nerd rank
82/ 100
Median analyst target
$14
Analysts covering
12
Revenue$418.8M+0.8% y/y
Operating income$19.3M
Net income$4.5M
Free cash flow$10.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+21.2%
1M
+17.0%
YTD
+19.4%
1Y
+31.2%
From 52W high
−25.3%
From 52W low
+66.6%
$9
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IART stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Integra LifeSciences Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
82/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Growth
91
Issuance
79
Accruals
70
Momentum
61
Quality
55
Volatility
48
Revisions
43
Size
42

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (43): Analysts have, on balance, been cutting their forecasts.

Size (42): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IART stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IART, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Jan 26Apr 26Jul 26Oct 26IARTHigh $23Median $14Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
3 Buy7 Hold2 Sell
Low $13Median $14High $23

The green dot is the last close — the median target sits −5.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 10 moved it down.

DateFirmActionRatingTarget
27 Oct 2026UBSMaintainsNeutral$19 → $14
26 Oct 2026Truist SecuritiesMaintainsHold$15 → $13
22 Oct 2026BMO CapitalMaintainsMarket Perform$15 → $14
22 Oct 2026CitigroupMaintainsNeutral$15 → $14
22 Oct 2026CitizensMaintainsMarket Outperform$25 → $22
22 Oct 2026JP MorganMaintainsUnderweight$17 → $14
22 Oct 2026Wells FargoMaintainsEqual-Weight$15 → $13
14 Oct 2026Truist SecuritiesMaintainsHold$19 → $15
14 Oct 2026Truist SecuritiesMaintainsHold—
5 Oct 2026BMO CapitalMaintainsMarket Perform$18 → $15
5 Oct 2026BMO CapitalMaintainsMarket Perform—
5 Oct 2026CitigroupMaintainsNeutral—
5 Oct 2026CitigroupMaintainsNeutral$19 → $15
30 July 2026Wells FargoMaintainsEqual-Weight$15 → $18
30 July 2026Wells FargoMaintainsEqual-Weight—
28 July 2026UBSInitiatesNeutral$19
28 July 2026UBSInitiatesNeutral—
16 July 2026Truist SecuritiesMaintainsHold$14 → $19
16 July 2026Truist SecuritiesMaintainsHold—
9 July 2026BMO CapitalInitiatesMarket Perform$19

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IART appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IART vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Integra LifeSciences Holdings Corp. returned +31.2% against +14.8% for the S&P 500, dividends included.

IART vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26IARTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IART analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−5.0%
Analysts raising
0
Analysts cutting
3
Fundamentals

Integra LifeSciences Holdings Corp. (IART) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
79.8×

Cheaper than 9% of US stocks

Price / sales
0.6×

Cheaper than 77% of US stocks

Price / book
1.0×

Cheaper than 70% of US stocks

EV / EBITDA
8.7×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
2.3%

Higher than 33% of US stocks

Earnings growth (YoY)
0.8%

Higher than 37% of US stocks

Gross margin
52.5%

Higher than 65% of US stocks

Operating margin
10.1%

Higher than 64% of US stocks

Net margin
0.8%

Higher than 49% of US stocks

Returns & dividend
Return on equity
1.2%

Higher than 46% of US stocks

Return on assets
2.9%

Higher than 65% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Integra LifeSciences Holdings Corp. (IART) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Integra LifeSciences Holdings Corp. has a market value of $1.1B and an enterprise value of $2.8B.

  • Revenue in the twelve months to 30 June 2026: $1.6B. The latest quarter grew 2.3% year on year.

  • Net income over the same four quarters: −$7.2M, a −0.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.09.

  • Free cash flow in the twelve months to 30 June 2026: $11.6M.

  • Shares outstanding: 77.8M.

  • Trailing P/E: 79.8×; forward P/E: 5.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Integra LifeSciences Holdings Corp. employs 4,427 people — $372K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Nov 2026

Data provided by Twelve Data

Peers

IART vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
IARTIntegra LifeSciences Holdings Corp.$1.1B82
IRMDIRadimed Corp.$1.1B81
SIBNSI-BONE, Inc.$1.1B81
PRCTPROCEPT BioRobotics Corp.$1.2B44
LMRILumexa Imaging Holdings, Inc.$1.2B2
ATECAlphatec Holdings, Inc.$1.3B61
AORTArtivion, Inc.$1.3B50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Integra LifeSciences Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IART news & analysis

Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting

GlobeNewsWire · 30 Oct 2026positive

Integra LifeSciences announced it will participate in the 2026 Congress of Neurological Surgeons Annual Meeting, October 31–November 4, in Washington, D.C. The company plans to showcase its neurosurgery portfolio through interactive education, hands-on training and technologies.

Why it matters — The event will give IART visibility for its neurosurgery offerings and educational activities among neurosurgeons.

Integra LifeSciences: Progress Remains Frustratingly Slow, But Valuation Is Getting Interesting

Seeking Alpha · 23 Oct 2026neutral

Integra LifeSciences continues to face operational challenges, particularly in Wound Reconstruction, while restructuring and the returning CEO are presented as potential supports for a turnaround. The article notes possible recovery catalysts, including product relaunches and market normalization, and cites expectations for improving margins.

Why it matters — IART watchers may weigh persistent execution issues against the recovery opportunities and margin expectations discussed in the article.

Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop

Business Wire · 23 Oct 2026negative

Glancy Prongay Wolke & Rotter LLP announced an investigation into whether Integra LifeSciences may have violated federal securities laws. The announcement follows a disclosure dated October 2, 2026, and references a 21.2% share-price drop.

Why it matters — The investigation concerns potential claims by Integra investors and may be relevant to shareholders monitoring the company’s legal and disclosure developments.

Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.

Business Wire · 23 Oct 2026negative

The Law Offices of Howard G. Smith said it is investigating whether Integra LifeSciences may have violated federal securities laws. The announcement follows a company disclosure dated October 2, 2026.

Why it matters — The investigation concerns potential legal claims by Integra investors who suffered losses and may be relevant to shareholders tracking legal and regulatory developments.

Lost Money on Integra LifeSciences Holdings Corporation Shares? The Law Offices of Frank R.

Business Wire · 22 Oct 2026negative

The Law Offices of Frank R. Cruz announced an investigation into potential securities fraud claims on behalf of Integra LifeSciences investors. The investigation examines whether the company may have violated federal securities laws, focusing on its disclosures.

Why it matters — IART watchers may wish to note the announced investigation into the company’s disclosures and potential investor claims.

FAQ

Frequently asked questions about IART stock

What is the IART stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Integra LifeSciences Holdings Corp. have a median 12-month price target of $14, with estimates ranging from $13 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IART stock a buy right now?

Of the 12 analysts covering Integra LifeSciences Holdings Corp., 3 rate it a Buy, 7 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Integra LifeSciences Holdings Corp. 82 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IART?

As at 4 Nov 2026, Integra LifeSciences Holdings Corp. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will IART stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies -5.6% from the last close, and Ticker Nerd's factor model ranks Integra LifeSciences Holdings Corp. 82 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IART stock forecast for 2030?

No analyst covering Integra LifeSciences Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IART are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $23 over the next 12 months.

How has IART stock performed over the past year?

Integra LifeSciences Holdings Corp. returned +31.2% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Integra LifeSciences Holdings Corp. do?

Integra LifeSciences Holdings Corporation is a medical technology company that develops, manufactures, and markets products used in neurosurgery, regenerative medicine, and surgical reconstruction. The company’s current business is organized around two main segments, Codman Specialty Surgical and Tissue Technologies, which support procedures in neurosurgery, neurocritical care, otolaryngology, wound repair, and tissue reconstruction.

What is the latest news on IART?

The most recent item we track (GlobeNewsWire, 30 Oct 2026): "Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting". Integra LifeSciences announced it will participate in the 2026 Congress of Neurological Surgeons Annual Meeting, October 31–November 4, in Washington, D.C. The company plans to showcase its neurosurgery portfolio through interactive education, hands-on training and technologies.

Company

About Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation is a medical technology company that develops, manufactures, and markets products used in neurosurgery, regenerative medicine, and surgical reconstruction. The company’s current business is organized around two main segments, Codman Specialty Surgical and Tissue Technologies, which support procedures in neurosurgery, neurocritical care, otolaryngology, wound repair, and tissue reconstruction. Its portfolio includes surgical instruments, dural repair products, cerebrospinal fluid management devices, cranial stabilization tools, and regenerative tissue technologies designed for complex wound and reconstructive care. Integra LifeSciences Holdings Corporation serves hospitals, surgery centers, and specialist clinicians across a range of medical disciplines, making it an important supplier in the healthcare equipment market. Headquartered in Princeton, New Jersey, the company focuses on providing clinically oriented solutions for procedures that require precision, reliability, and specialized surgical support.

CEO Dr. Stuart M. Essig Ph.D. · 4,427 employees · United States · https://www.integralife.com